开云app官网登录入口网页版-官方正版

#头颈鳞状细胞癌#

7篇内容 | 993人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2215192, encodeId=a2b822151922e, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=9e41116e3433' target=_blank style='color:#2F92EE;'>#Eftilagimod alpha#</a>, objectTitle=CLIN CANCER RES | 联合使用Eftilagimod和帕博利珠单抗治疗复发性/转移性头颈鳞状细胞癌的疗效和安全性分析, objectType=article, longId=834728, objectId=414e834e2887, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240715/1721050565636_6145188.png, objectUrl=/article/show_article.do?id=414e834e2887, replyNumber=0, likeNumber=60, createdTime=2024-07-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=414e834e2887, moduleTitle=CLIN CANCER RES | 联合使用Eftilagimod和帕博利珠单抗治疗复发性/转移性头颈鳞状细胞癌的疗效和安全性分析, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=414e834e2887)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211925, encodeId=ab99221192563, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a> <a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a>, objectTitle=Lancet Oncol | 帕博利珠单抗联合化疗放疗在局部晚期头颈鳞状细胞癌中的疗效和安全性：KEYNOTE-412 试验结果, objectType=article, longId=831956, objectId=291f83195655, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719466371519_92910.jpg, objectUrl=/article/show_article.do?id=291f83195655, replyNumber=0, likeNumber=80, createdTime=2024-06-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=291f83195655, moduleTitle=Lancet Oncol | 帕博利珠单抗联合化疗放疗在局部晚期头颈鳞状细胞癌中的疗效和安全性：KEYNOTE-412 试验结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=291f83195655)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1614096, encodeId=df95161409611, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=60, createdTime=2022-01-23, rootId=0, userName=ms55066533437992, userId=54d419484077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1614095, encodeId=3d4d161409520, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌 , objectType=article, longId=221637, objectId=357d22163ea7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=357d22163ea7, replyNumber=0, likeNumber=69, createdTime=2021-12-08, rootId=0, userName=ms55066533437992, userId=54d419484077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=357d22163ea7, moduleTitle=Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌 , moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=357d22163ea7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1614094, encodeId=b5741614094aa, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=Lancet oncol：复发性/转移性头颈鳞状细胞癌患者的两种一线化疗方案对比！, objectType=article, longId=208161, objectId=dc7d20816104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7d20816104, replyNumber=0, likeNumber=79, createdTime=2021-03-09, rootId=0, userName=ms55066533437992, userId=54d419484077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7d20816104, moduleTitle=Lancet oncol：复发性/转移性头颈鳞状细胞癌患者的两种一线化疗方案对比！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dc7d20816104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1614093, encodeId=7d4916140937f, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=Eur J Cancer：局部晚期头颈鳞状细胞癌老年患者强化放疗激活NBTXR3的I期剂量递增研究, objectType=article, longId=207381, objectId=313020e38117, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313020e38117, replyNumber=0, likeNumber=58, createdTime=2021-02-22, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313020e38117, moduleTitle=Eur J Cancer：局部晚期头颈鳞状细胞癌老年患者强化放疗激活NBTXR3的I期剂量递增研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=313020e38117)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1614092, encodeId=b52516140925f, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=J Dent Res：NOTCH通路在头颈鳞状细胞癌中的研究进展, objectType=article, longId=138851, objectId=d9ac138851b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9ac138851b0, replyNumber=0, likeNumber=71, createdTime=2018-05-24, rootId=0, userName=ms55066533437992, userId=54d419484077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9ac138851b0, moduleTitle=J Dent Res：NOTCH通路在头颈鳞状细胞癌中的研究进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d9ac138851b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1614091, encodeId=74611614091a0, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=J Dent Res：头颈鳞状细胞癌的精准医疗, objectType=article, longId=138791, objectId=1703138e91fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1703138e91fb, replyNumber=0, likeNumber=75, createdTime=2018-05-23, rootId=0, userName=ms55066533437992, userId=54d419484077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1703138e91fb, moduleTitle=J Dent Res：头颈鳞状细胞癌的精准医疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1703138e91fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1614090, encodeId=11e816140901f, content=<a href='/topic/show?id=17244443870' target=_blank style='color:#2F92EE;'>#头颈鳞状细胞癌#</a>, objectTitle=NEJM：Nivolumab可延长复发性头颈鳞状细胞癌患者的总生存期, objectType=article, longId=79706, objectId=03fbe9706d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fbe9706d9, replyNumber=0, likeNumber=74, createdTime=2016-10-12, rootId=0, userName=ms55066533437992, userId=54d419484077, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fbe9706d9, moduleTitle=NEJM：Nivolumab可延长复发性头颈鳞状细胞癌患者的总生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=03fbe9706d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

头颈鳞状细胞癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌# #帕博利珠单抗# #Eftilagimod alpha#

CLIN CANCER RES | 联合使用Eftilagimod和帕博利珠单抗治疗复发性/转移性头颈鳞状细胞癌的疗效和安全性分析

2024-07-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#放化疗# #头颈鳞状细胞癌# #帕博利珠单抗#

Lancet Oncol | 帕博利珠单抗联合化疗放疗在局部晚期头颈鳞状细胞癌中的疗效和安全性：KEYNOTE-412 试验结果

2024-06-27发表于上海

ms55066533437992 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-01-23

ms55066533437992 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌

2021-12-08

ms55066533437992 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

Lancet oncol：复发性/转移性头颈鳞状细胞癌患者的两种一线化疗方案对比！

2021-03-09

hb2008ye (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

Eur J Cancer：局部晚期头颈鳞状细胞癌老年患者强化放疗激活NBTXR3的I期剂量递增研究

2021-02-22

ms55066533437992 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

J Dent Res：NOTCH通路在头颈鳞状细胞癌中的研究进展

2018-05-24

ms55066533437992 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

J Dent Res：头颈鳞状细胞癌的精准医疗

2018-05-23

ms55066533437992 (审核中...)

前往app查看评论内容

#头颈鳞状细胞癌#

NEJM：Nivolumab可延长复发性头颈鳞状细胞癌患者的总生存期

2016-10-12

科室
- - 订阅+
  - 更多科室
工具
服务